Eliana Merle
Stock Analyst at UBS
(0.48)
# 2225
Out of 5,319 analysts
89
Total ratings
30.95%
Success rate
-9.22%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BMRN Biomarin Pharmaceuti... | Maintains: Strong Buy | 109 113 | 59.17 | 90.98% | 2 | Feb 20, 2025 | |
MRNA Moderna | Maintains: Buy | 96 78 | 24.71 | 215.66% | 6 | Feb 19, 2025 | |
ETNB 89bio | Maintains: Strong Buy | 25 38 | 6.06 | 527.06% | 3 | Jan 31, 2025 | |
AKRO Akero Therapeutics | Maintains: Strong Buy | 42 109 | 37.63 | 189.66% | 4 | Jan 31, 2025 | |
ZNTL Zentalis Pharma | Maintains: Neutral | 5 3 | 1.29 | 70.54% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 71 | 36.76 | 93.14% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 196 | 165.05 | 18.75% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 28 | 8.92 | 213.9% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 12 | 2.21 | 442.99% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 3 | 3.36 | -10.71% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 26 | 4.55 | 471.43% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 80 74 | 25.97 | 184.94% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 411 441 | 301.66 | 46.19% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 23 33 | 20.55 | 60.58% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 97 131 | 98.76 | 32.64% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 10 2 | 0.79 | 153.16% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 85 83 | 18.2 | 356.04% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 253 288 | 234.56 | 22.78% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 51 47 | 33.87 | 38.77% | 2 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 3 5 | 2.84 | 76.06% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 18 | 2.4 | 650% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 33 | n/a | n/a | 7 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 45 42 | 13 | 223.08% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 34 40 | n/a | n/a | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 18 | 3.12 | 476.92% | 1 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 8 | 0.84 | 852.38% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 22 | 4.55 | 383.52% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 51 47 | 5.94 | 691.25% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 9 | n/a | n/a | 1 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 16 | 6.83 | 134.26% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 123 | 8.6 | 1330.23% | 3 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 192 134 | 24.66 | 443.39% | 3 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 121 | n/a | n/a | 1 | Apr 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 10 | n/a | n/a | 1 | Jan 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 57 68 | n/a | n/a | 2 | Oct 22, 2018 |